Intrinsiqq
Lakefront Biotherapeutics logo

Lakefront Biotherapeutics Quality Score

LKFT.XAMS

Compare
Quality28

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
100/100
3.4x

Under 20x, reasonable relative to earnings

Cash Flow Multiple
0/100
-8.6x

Negative FCF, no valuation support

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Capital Structure
100/100
-€2.99B

Net cash position, no leverage concern

2025
€3.00B
€7.00M
CashDebt
Return on Capital
80/100
15.5%

15–20%, well above cost of capital

Customize WeightsPremiumUpgrade

Lakefront Biotherapeutics (LKFT.XAMS) quality: score, margins and returns

Lakefront Biotherapeutics (LKFT.XAMS) scores 28/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100, on 61.6% operating margins and 15.5% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Lakefront Biotherapeutics (LKFT.XAMS) a high-quality business?+

Lakefront Biotherapeutics scores 28 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a 61.6% operating margin and a 15.5% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Lakefront Biotherapeutics's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from LKFT.XAMS's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Lakefront Biotherapeutics scores well and where it falls behind.

What is Lakefront Biotherapeutics's return on invested capital (ROIC)?+

Lakefront Biotherapeutics earns about 15.5% on its invested capital, which is strong. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to LKFT.XAMS's margins and growth on this scorecard to judge durability.

How profitable is Lakefront Biotherapeutics?+

Lakefront Biotherapeutics runs an operating margin of about 61.6% and a net margin of about 60.2%. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

More on LKFT.XAMS: Overview · DCF valuation · Dividend safety · Financials
How the market compares: US profitability statistics

Peers

Biotechnology · Pick stocks to compare with LKFT.XAMS

CompareIntrinsic value
GLPGGalapagos NV American Depositary Receipt
$33.39-2.00%61
ASNDAscendis Pharma A/S
$252.73-1.26%59
LMRILumexa Imaging Holdings, Inc.
$14.10+0.25%42
SFL.XMILSafilo Group S.p.A.
€2.06-6.78%69
SUS.XSTOSurgical Science Sweden AB
kr 59.75+0.76%37
DOCM.XSWXDocMorris AG
CHF 18.63-0.90%26
FAGR.XBRUFagron NV
€24.65+1.02%78
DMP.XETRDermapharm Holding SE
€32.75-2.09%49

Held by ETFs

LKFT.XAMS is in 10 US ETFs. The largest of them, with LKFT.XAMS's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing LKFT.XAMS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.